stars 1 stars 2 stars 3

Epicardio is a MedTech company developing intelligent cardiac simulation software. Epicardio Simulation™ is an electromechanical model of the heart, capable of reproducing complex arrhythmic states, responding to external stimulation, such as pacing, ablation and drug administration, while generating accurate action potential wavefront and ECG/EGM signals in real-time. Epicardio develops and commercialises training apps for Cardiology, targeted to medical schools, hospitals and the cardiac devices industry. Epicardio apps are used globally by leading med schools, such as Oxford, Cambridge, Karolinska, etc. Our industry customers include Schiller, Medtronic, Boston Scientific, Abbott, etc. We aim to become global leader in simulation-based medical training and diagnosis support, improving access and reducing costs and patient risk. We are currently building a world-class range of intelligent simulation software to be sold to multiple international markets, and to accomplish this, we believe in creating a first-class working environment. If you would like to discuss opportunities with Epicardio, email us: contact (at) epicardio (dot) com.

Epicardio Questions

The Epicardio annual revenue was $6 million in 2026.

Vassilios Hurmusiadis is the Founder and CEO of Epicardio.

1 people are employed at Epicardio.

The NAICS codes for Epicardio are [5415, 54151, 541, 541511, 54].

The SIC codes for Epicardio are [73, 737].

Top Epicardio Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users